UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 127

Sortiert nach

A Phase III open-label trial to evaluate efficacy and safety of CPI-613 plus modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) in patients with metastatic adenocarcinoma of the pancreas

Future oncology (London, England), 2019-10, Vol.15 (28), p.3189-3196

2019

Link zum Volltext

Verfügbarkeit prüfen

Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer

Journal of clinical oncology, 2024-03, Vol.42 (9), p.1044

2024

Link zum Volltext

Verfügbarkeit prüfen

Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial

Journal of neuro-oncology, 2016-05, Vol.128 (1), p.163-171

2016

Link zum Volltext

Verfügbarkeit prüfen

Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in women with locally advanced HER2-negative breast cancer: NSABP Foundation Study FB-9

Breast cancer research and treatment, 2015-07, Vol.152 (2), p.399-405

2015

Link zum Volltext

Verfügbarkeit prüfen

The Evaluation of Surrogate Endpoints

1, 2005

Link zum Volltext

Verfügbarkeit prüfen

Design and Analysis of Clinical Trials for Predictive Medicine

1, 2015

Link zum Volltext

Verfügbarkeit prüfen

Concurrent Bevacizumab with a Sequential Regimen of Doxorubicin and Cyclophosphamide Followed by Docetaxel and Capecitabine as Neoadjuvant Therapy for HER2− Locally Advanced Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group

Clinical breast cancer, 2011-08, Vol.11 (4), p.228-234

2011

Link zum Volltext

Verfügbarkeit prüfen

Multicentre, Open Label, Randomized Phase III Study of Cpi-613® (devimistat) in Combination with High Dose Cytarabine and Mitoxantrone (CHAM) Compared to High Dose Cytarabine and Mitoxantrone (HAM) in Older Patients (≥ 60 years) with Relapsed / Refractory Acute Myeloid Leukemia (AML) - Armada 2000 (AML003) Trial

Blood, 2019-11, Vol.134 (Supplement_1), p.2658-2658

2019

Link zum Volltext

Verfügbarkeit prüfen

Time trends in overall survival (OS) and progression-free survival (PFS) in the first-line treatment of advanced non-small-cell lung cancer (NSCLC)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e20580-e20580

2016

Link zum Volltext

Verfügbarkeit prüfen

Assessing PSA levels as prognostic of overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.5070-5070

2023

Link zum Volltext

Verfügbarkeit prüfen

Randomized controlled phase III trial of weekly paclitaxel ± ofranergene obadenovec (VB-111) for platinum-resistant ovarian cancer (OVAL Study/GOG 3018)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.5505-5505

2023

Link zum Volltext

Verfügbarkeit prüfen

The relationship between a priori defined prognostic risk groups and and overall survival (OS) in men with metastatic hormone sensitive prostate cancer (mHSPC)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.5073-5073

2023

Link zum Volltext

Verfügbarkeit prüfen

REGINA: A phase II trial of neoadjuvant regorafenib (Rego) in combination with nivolumab (Nivo) and short-course radiotherapy (SCRT) in intermediate-risk, stage II-III rectal cancer (RC)

Journal of clinical oncology, 2022-02, Vol.40 (4_suppl), p.TPS226-TPS226

2022

Link zum Volltext

Verfügbarkeit prüfen

Phase 3, multicenter, randomized study of CPI-613 with modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) as first-line therapy for patients with metastatic adenocarcinoma of the pancreas (AVENGER500)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.4023-4023

2022

Link zum Volltext

Verfügbarkeit prüfen

Assessing intermediate clinical endpoints (ICE) as potential surrogates for overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.5006-5006

2022

Link zum Volltext

Verfügbarkeit prüfen

Impact of follow-up on generalized pairwise comparisons for estimating the irinotecan benefit in advanced/metastatic gastric cancer

Contemporary clinical trials, 2021-06, Vol.105, p.106400-106400, Article 106400

2021

Link zum Volltext

Verfügbarkeit prüfen

Avenger 500, a phase III open-label randomized trial of the combination of CPI-613 with modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) in patients with metastatic adenocarcinoma of the pancreas

Journal of clinical oncology, 2019-02, Vol.37 (4_suppl), p.TPS479-TPS479

2019

Link zum Volltext

Verfügbarkeit prüfen

Progression-free survival (PFS) as a surrogate endpoint for overall survival (OS) in advanced/recurrent gastric cancer (AGC) treatment: Individual-patient-data (IPD) based meta-analysis of randomized trials

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e16506-e16506

2020

Link zum Volltext

Verfügbarkeit prüfen

Comparing the outcomes of noninferiority (NI) and superiority phase III trials

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.e13055-e13055

2012

Link zum Volltext

Verfügbarkeit prüfen

Tumor-size-based endpoints as surrogates for overall survival in the ARCAD Advanced Colorectal Cancer Database

Journal of clinical oncology, 2017-02, Vol.35 (4_suppl), p.766-766

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 127

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(120)
Mit Volltextzugriff
(119)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(57)
Science & Technology
(57)
Humans
(47)
Oncology
(36)
Female
(33)
Middle Aged
(26)
Biological And Medical Sciences
(25)
Medical Sciences
(24)
Adult
(20)
Aged
(19)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(19)
Male
(19)
Tumors
(19)
Chemotherapy
(17)
Disease-Free Survival
(17)
Clinical Trials
(16)
Treatment Outcome
(15)
Prognosis
(14)
Breast Neoplasms - Drug Therapy
(11)
Survival Analysis
(10)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial

A Phase III open-label trial to evaluate efficacy and safety of CPI-613 plus modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) in patients with metastatic adenocarcinoma of the pancreas

Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer

Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non‐inferiority, phase III trial of second‐line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab

Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial

Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS)

Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in women with locally advanced HER2-negative breast cancer: NSABP Foundation Study FB-9

The Evaluation of Surrogate Endpoints

Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5

Design and Analysis of Clinical Trials for Predictive Medicine

Individual patient data (IPD) analysis of progression-free survival (PFS) versus overall survival (OS) as an endpoint for metastatic colorectal cancer (mCRC) in modern trials: Findings from the 16,700 patients (pts) ARCAD database

Concurrent Bevacizumab with a Sequential Regimen of Doxorubicin and Cyclophosphamide Followed by Docetaxel and Capecitabine as Neoadjuvant Therapy for HER2− Locally Advanced Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group

Time trends in overall survival (OS) and progression-free survival (PFS) in the first-line treatment of advanced non-small-cell lung cancer (NSCLC)

Assessing PSA levels as prognostic of overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC)

Randomized controlled phase III trial of weekly paclitaxel ± ofranergene obadenovec (VB-111) for platinum-resistant ovarian cancer (OVAL Study/GOG 3018)

The relationship between a priori defined prognostic risk groups and and overall survival (OS) in men with metastatic hormone sensitive prostate cancer (mHSPC)

REGINA: A phase II trial of neoadjuvant regorafenib (Rego) in combination with nivolumab (Nivo) and short-course radiotherapy (SCRT) in intermediate-risk, stage II-III rectal cancer (RC)

Phase 3, multicenter, randomized study of CPI-613 with modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) as first-line therapy for patients with metastatic adenocarcinoma of the pancreas (AVENGER500)

Assessing intermediate clinical endpoints (ICE) as potential surrogates for overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC)

Impact of follow-up on generalized pairwise comparisons for estimating the irinotecan benefit in advanced/metastatic gastric cancer

Avenger 500, a phase III open-label randomized trial of the combination of CPI-613 with modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) in patients with metastatic adenocarcinoma of the pancreas

Progression-free survival (PFS) as a surrogate endpoint for overall survival (OS) in advanced/recurrent gastric cancer (AGC) treatment: Individual-patient-data (IPD) based meta-analysis of randomized trials

Comparing the outcomes of noninferiority (NI) and superiority phase III trials

Tumor-size-based endpoints as surrogates for overall survival in the ARCAD Advanced Colorectal Cancer Database

Suchergebnisse filtern